📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
395 analysed today
FollowTelegram
395
Today
149,796
All-time analysed
42,945
Positive
6,666
Negative
91,495
Neutral
8,622
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Vimta Labs Q3 Net Profit at ₹175.86 Mn; 9M Revenue Grows 19% YoY
Vimta Labs reported a steady Q3 FY26 with revenue from operations reaching ₹986.33 million, a 9.7% growth compared to the same quarter last year. Net profit for the quarter stood at ₹175.86 million, which remained relatively flat YoY due to a one-time exceptional charge of ₹16.16 million related to new labor code compliance. For the nine-month period ending December 2025, the company showed robust performance with total income rising to ₹3,042.83 million from ₹2,521.41 million in the previous year. The company has successfully transitioned its focus to core contract research and testing services following the divestment of its diagnostic business.
Key Highlights
Revenue from operations for Q3 FY26 grew 9.7% YoY to ₹986.33 million.
Net Profit for the nine-month period (9M FY26) increased by 16.4% to ₹563.99 million.
Recorded a one-time exceptional expense of ₹16.16 million for gratuity adjustments under new labor codes.
Basic EPS for the quarter stood at ₹3.96, adjusted for the 1:1 bonus issue completed in June 2025.
The Board approved the grant of 38,269 new ESOP options to eligible employees.
👀 What to Watch
Investors should monitor the company's ability to maintain margins in its core testing segment now that the lower-margin diagnostic business has been divested. The steady YoY growth in the nine-month period suggests a positive trajectory for the core business.
Vimta Labs Q3 Revenue Grows 9.7% YoY to ₹986M; PAT at ₹175.8M Impacted by Exceptional Item
Vimta Labs reported a steady 9.7% year-on-year growth in revenue from continuing operations, reaching ₹986.33 million for Q3 FY26. Net Profit for the quarter stood at ₹175.86 million, a decline from ₹214.96 million in the previous year's quarter, largely due to a ₹16.16 million exceptional charge related to new labor codes and the absence of discontinued diagnostic business income. Employee benefit expenses saw a significant rise to ₹284.05 million compared to ₹233.66 million YoY. The company has now fully transitioned away from its diagnostic business, focusing entirely on contract research and testing services.
Key Highlights
Revenue from operations increased 9.7% YoY to ₹986.33 million in Q3 FY26.
Net Profit for the quarter stood at ₹175.86 million, down from ₹214.96 million in Q3 FY25.
Recorded an exceptional item of ₹16.16 million due to the statutory impact of new Labour Codes.
Employee benefit expenses rose by 21.5% YoY to ₹284.05 million.
Nine-month revenue for FY26 reached ₹2,980.45 million, up from ₹2,495.41 million in the previous year.
👀 What to Watch
Investors should monitor the company's margin profile as it navigates rising employee costs and the impact of new labor regulations. While core revenue growth remains healthy, the stock's performance will depend on the successful scaling of its contract research services post-divestment of the diagnostics arm.
Vimta Labs Q3 PAT at ₹175.9M; Revenue Grows 9.7% YoY to ₹986.3M
Vimta Labs reported a steady 9.7% year-on-year growth in revenue from operations, reaching ₹986.33 million for Q3 FY26. Net profit for the quarter stood at ₹175.86 million, remaining nearly flat compared to ₹175.16 million from continuing operations in the same quarter last year. The bottom line was impacted by a one-time exceptional charge of ₹16.16 million due to the implementation of new labor codes. The company is now fully focused on its core Contract Research and Testing Services following the divestment of its diagnostics business to Thyrocare.
Key Highlights
Revenue from operations increased 9.7% YoY to ₹986.33 million from ₹899.23 million.
Net Profit for the quarter stood at ₹175.86 million, facing a sequential decline from ₹199.20 million in Q2.
Recognized an exceptional item of ₹16.16 million related to past service costs for gratuity under new Labour Codes.
Nine-month (9M FY26) revenue reached ₹2,980.45 million, up 19.4% compared to ₹2,495.41 million in 9M FY25.
The Board approved the grant of 38,269 new ESOP options to eligible employees.
👀 What to Watch
Investors should monitor the company's margin stability as it scales its core research business post-diagnostics divestment. While YoY growth is healthy, the sequential dip in performance suggests a need for cautious observation of upcoming quarters.
